Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial
/in Dendritic Cells, Glioblastoma, International PublicationsPilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients
/in Dendritic Cells, International PublicationsLong-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma
/in Colorectal Cancer, Dendritic Cells, International PublicationsPhase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission
/in Dendritic Cells, International Publications, Ovarian CancerCombination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial
/in Breast Cancer, Dendritic Cells, Hypernephroma, International PublicationsImproved efficacy of therapeutic vaccination with dendritic cells pulsed with tumor cell lysate against hepatocellular carcinoma by introduction of 2 tandem repeats of microbial HSP70 peptide epitope 407-426 and OK-432
/in Dendritic Cells, Hepatocellular Carcinoma, International PublicationsInduction of tolerogenic dendritic cells by IL-6-secreting CT26 colon carcinoma
/in Colorectal Cancer, Dendritic Cells, International PublicationsCurrent vaccination strategies for prostate cancer
/in Dendritic Cells, International Publications, Prostate CancerProving the principle: dendritic cell-based vaccines in urogenital cancers
/in Dendritic Cells, Hypernephroma, International Publications, Prostate Cancer
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer